Eli Lilly Drops 3.3% on Rare Sell Rating — Is Wall Street's Obesity Bet Too Big?

Shares slid as HSBC analyst Rajesh Kumar issued the only sell-equivalent rating on Eli Lilly across Wall Street, downgrading LLY to "Reduce" from "Hold" and cutting his price target to $850 from $1,070 — roughly 11% below today's $956.50 close. The move challenges the biggest growth story in pharma and raises a pointed question: what if the weight-loss drug market isn't as large as Lilly's stock price assumes?

• The Obesity Market May Be Billions Smaller Than Everyone Thinks. Kumar argues that consensus expectations for weight-loss drugs — roughly $150 billion by the end of the decade — are "due for correction," pegging the realistic range at $80–$120 billion by 2032, with significant pricing competition on top. That gap is enormous. Lilly's two flagship injectables, Zepbound and Mounjaro, already generated $11.67 billion of the company's $19.29 billion in Q4 2025 revenue — over 60% of the total. A smaller market ceiling directly compresses the revenue runway investors are paying a 43x trailing earnings multiple to access.

• Lilly's Coming Weight-Loss Pill May Not Live Up to the Hype. The company's oral obesity pill, awaiting FDA approval expected by April, has generated real excitement, with consensus 2026 sales forecasts of $1.1–$1.3 billion.

But HSBC warns that patient compliance and persistence rates for oral drugs "may disappoint" and that clinical trial dropout rates suggest current assumptions are too high.

Lilly's pill does have one edge: unlike Novo Nordisk's competing oral drug, it has no food or water restrictions — a convenience factor the company is banking on.

• Falling Prices Are Already Eating Into Revenue Quality. Lilly's own filings show volume is carrying the revenue load while prices fall — U.S. prices declined by high single digits in Q3 2025, with 10% lower realized prices partially offsetting 62% volume growth.

HSBC notes Lilly's outperformance over rival Novo Nordisk has been driven largely by the cash-pay channel — customers paying out of pocket rather than through insurance — a revenue stream vulnerable to economic downturns.

• Lilly's Own Guidance Tells a Very Different Story. The company guided to 2026 revenue of $80–$83 billion, well above analyst expectations , implying roughly 25% growth this year.

Its pipeline extends well beyond obesity into cardiovascular disease, oncology, Alzheimer's, and immunology. HSBC's Kumar concedes execution has been strong but warns the stock is simply "priced to perfection" — meaning any stumble gets punished. With rival Novo Nordisk down 55% over the past year, investors must decide whether Lilly is the exception or just next in line.